Enovix (NASDAQ:ENVX) Reaches New 1-Year Low After Analyst Downgrade

Enovix Corporation (NASDAQ:ENVX)’s stock price reached a new 52-week low during trading on Friday after Canaccord Genuity Group lowered their price target on the stock from $21.00 to $15.00. Canaccord Genuity Group currently has a buy rating on the stock. Enovix traded as low as $5.25 and last traded at $5.2940, with a volume of 6870811 shares traded. The stock had previously closed at $5.95.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald dropped their price target on shares of Enovix from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. JPMorgan Chase & Co. dropped their target price on shares of Enovix from $12.00 to $10.00 and set a “neutral” rating on the stock in a report on Wednesday, November 12th. Craig Hallum decreased their price target on shares of Enovix from $16.00 to $10.00 and set a “buy” rating for the company in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovix in a research report on Monday, December 29th. Finally, Northland Securities set a $16.00 price target on Enovix in a report on Monday, November 17th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $15.65.

Key Enovix News

Here are the key news stories impacting Enovix this week:

• Positive Sentiment: Q4 results beat expectations: revenue of ~$11.3M (+~16% YoY) topped estimates and EPS/loss was slightly better than forecast; gross profit and operating-loss improvement were highlighted on the call — a fundamental bright spot supporting longer‑term growth potential. SA Q4 Presentation
• Positive Sentiment: Multiple outlets noted the revenue and EPS beats and operational improvement (higher gross profit, narrower operating loss), which help the growth narrative even as profitability remains distant. Yahoo Finance: Q4 Report
• Neutral Sentiment: Unusual options activity: a large block of call buying (≈31,896 calls) indicates speculative/leveraged interest that may amplify intraday moves but doesn’t change fundamentals. AAII Options Note
• Neutral Sentiment: Some analysts lowered price targets but kept constructive ratings (e.g., Canaccord trimmed its PT but remains “Buy”), which mutes upside while signaling continued long‑term conviction from parts of the sell‑side. Benzinga: Canaccord Note
• Negative Sentiment: Near‑term guidance disappointed: Q1 FY2026 revenue guidance ($6.5M–$7.5M) came in well below consensus (~$8.8M), a key proximate reason for selling pressure as it implies slower near‑term growth. Company Press Release / Deck
• Negative Sentiment: Analyst downgrades/target cuts: TD Cowen cut its target sharply and moved to “Hold,” and other firms trimmed targets — increasing near‑term downside risk as sell‑side expectations are reset. Benzinga: TD Cowen Note
• Negative Sentiment: New risk disclosure highlights rising geopolitical/trade exposure (U.S.–China tensions) that could pressure supply chains and margins — a fresh governance/operational risk investors must price in. TipRanks: Risk Disclosure
• Negative Sentiment: Balance‑sheet and liquidity signals are concerning to some investors: cash fell year‑over‑year and total liabilities rose materially; coupled with insider sales called out in reporting, that has likely amplified selling. Quiver Quant: Financials

Institutional Trading of Enovix

A number of institutional investors and hedge funds have recently modified their holdings of ENVX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Enovix by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 98,318 shares of the company’s stock valued at $722,000 after purchasing an additional 4,780 shares in the last quarter. NewEdge Advisors LLC raised its stake in shares of Enovix by 10.4% in the 1st quarter. NewEdge Advisors LLC now owns 26,257 shares of the company’s stock valued at $193,000 after buying an additional 2,481 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Enovix by 65.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,137,777 shares of the company’s stock worth $8,351,000 after acquiring an additional 449,934 shares during the period. Caxton Associates LLP acquired a new stake in shares of Enovix during the 1st quarter valued at about $190,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Enovix by 18.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 358,023 shares of the company’s stock valued at $2,628,000 after acquiring an additional 55,676 shares during the period. 50.92% of the stock is currently owned by institutional investors.

Enovix Stock Performance

The firm has a market cap of $1.14 billion, a P/E ratio of -6.84 and a beta of 2.13. The company has a debt-to-equity ratio of 1.74, a current ratio of 9.72 and a quick ratio of 9.47. The stock’s 50 day moving average is $7.10 and its two-hundred day moving average is $8.88.

Enovix Company Profile

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.